Holen Sie sich die Stockscreener-App
29.36
3.89%
-1.205
Schlusskurs vom Vortag:
$30.56
Offen:
$29.74
24-Stunden-Volumen:
1.28M
Relative Volume:
0.65
Marktkapitalisierung:
$3.02B
Einnahmen:
$139.74M
Nettoeinkommen (Verlust:
$-79.99M
KGV:
-28.90
EPS:
-1.0157
Netto-Cashflow:
$-360.05M
1W Leistung:
-7.32%
1M Leistung:
+32.36%
6M Leistung:
+18.57%
1J Leistung:
+49.01%
1-Tages-Spanne:
$28.69
$30.28
1-Wochen-Bereich:
$27.10
$32.15
52-Wochen-Spanne:
$15.35
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.35 | 3.14B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
423.58 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
683.60 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
767.07 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.07 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.50 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Insider Monkey
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Beam Therapeutics shows rising relative strength; still shy of key benchmark - MSN
Beam Therapeutics (BEAM) Shares Surge 10.7% on Positive Market Momentum - GuruFocus
Beam Therapeutics (BEAM) Shares Surge 10.7% on Positive Market M - GuruFocus
S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data - Investing.com
Beam Therapeutics (BEAM) Shares Rise Over 10% Amid Positive Mark - GuruFocus
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
Beam Therapeutics (BEAM) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Beam Therapeutics (BEAM) Q4 2025 earnings summary - Quartr
Beam Therapeutics (BEAM) Q3 2024 earnings summary - Quartr
Beam Therapeutics (BEAM) Status Update Summary - Quartr
Beam Therapeutics (BEAM) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Beam Therapeutics (BEAM) Jefferies London Healthcare Conference 2024 Summary - Quartr
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates - MSN
Stocks flashing renewed technical strength: Beam Therapeutics - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.7%What's Next? - MarketBeat
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BEAM Price Today: Beam Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
This Beam Therapeutics Insider Reduced Their Stake By 42% - 富途牛牛
(BEAM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Executive pay and board elections at Beam Therapeutics (NASDAQ: BEAM) 2026 virtual meeting - Stock Titan
[ARS] Beam Therapeutics Inc. SEC Filing - Stock Titan
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit FacilityHas The Bull Case Changed? - Yahoo Finance
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
Sumitomo Mitsui Trust Group Inc. Has $122.23 Million Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Baillie Gifford & Co. Boosts Beam Therapeutics Stake by 40% - National Today
Baillie Gifford & Co. Acquires 118,421 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Up 9.1%Here's What Happened - MarketBeat
Beam Therapeutics CEO Sells 30,078 Shares in April 2026 Transaction | Stock UpdateNews and Statistics - IndexBox
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - Yahoo Finance
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Beam Therapeutics President Sells $290,289 in Stock - National Today
(BEAM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Beam Therapeutics CEO Sells Over $700K in Stock - National Today
BEAM Forecast, Price Target & Analyst Ratings | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Insider Sells $146K in Shares - National Today
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock By Investing.com - Investing.com Australia
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock By Investing.com - Investing.com India
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares of Stock - MarketBeat
John Evans Sells 30,078 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares - MarketBeat
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock By Investing.com - Investing.com Australia
Beam Therapeutics president sells $290k in shares By Investing.com - Investing.com Australia
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beam Therapeutics Inc-Aktie (BEAM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '26 |
Sale |
24.58 |
30,078 |
739,317 |
1,047,205 |
| Simon Amy | Chief Medical Officer |
Apr 01 '26 |
Sale |
24.58 |
6,700 |
164,686 |
102,735 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '26 |
Sale |
24.58 |
3,242 |
79,688 |
51,171 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '26 |
Sale |
24.58 |
5,956 |
146,398 |
109,711 |
| Ciaramella Giuseppe | President |
Apr 01 '26 |
Sale |
24.58 |
11,810 |
290,290 |
218,406 |
| Evans John M. | CEO |
Mar 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Sale |
22.76 |
25,000 |
569,085 |
986,667 |
| Evans John M. | CEO |
Mar 30 '26 |
Sale |
22.37 |
25,000 |
559,230 |
986,667 |
3.17%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):